Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
SDĚLENÍ
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx se xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Sb. x. x., č. 46/2008 Xx. x. x. a x. 47/2012 Xx. m. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu
Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, že xxx 16. xxxxxxxxx 2011 xxxx generální xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Přílohy X - Seznamu xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx dopingu ve xxxxxx.1)
X xxxxx xxxxxx Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx republiky.
Xxxx xxxxx Přílohy X xxxxxxxxx x platnost x souladu x xxxxxxx 34 odst. 3 Xxxxxx xxx 1. ledna 2012 x xxxxx xxxx xxxxxxxxx x platnost x pro Xxxxxx xxxxxxxxx. Xxxx vstupu xxxxxx xxxxx Xxxxxxx X x platnost xxxxxxxx xxxxxx xxxxx Xxxxxxx I Mezinárodní xxxxxx xxxxx xxxxxxx xx sportu platné xx 1. xxxxx 2011 x xxxxxxxxx xxx č. 47/2012 Sb. m. s.
Xxxxxxxx xxxxx Přílohy X x její xxxxxxx xx českého xxxxxx xx xxxxxxxxx současně.
1) Mezinárodní xxxxxx proti xxxxxxx xx sportu přijatá xxx 19. xxxxx 2005 x Paříži xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s.
XXXXXXXXXXX XXXXXX XXXXX DOPINGU XX XXXXXX
Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx a xxxxx - Mezinárodní xxxxxxxx
Paříž, 1. xxxxx 2012
XXXXXX XXXXXXXXXX LÁTEK X XXXXX XXXXXXX PRO XXX 2012
XXXXXXX XXXXXXXXXXXXX KODEX
Xxxxxx xx 1. xxxxx 2012
Podle xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Zakázané xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx látky" xxxxx látek ze xxxxxx X1, X2, X4.4, X4.5 x X6(x) x Zakázaných xxxxx X1, X2 x M3.
XXXXX X METODY XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX) |
XXXXXXXX XXXXX
S0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx humánní xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxx xxxx po xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx léky), je xxxxxxxx xxxxx.
X1. XXXXXXXXXX XXXXX
Anabolické xxxxx xxxx xxxxxxxx.
1. XXXXXXXXXX ANABOLICKÉ XXXXXXXX (XXX):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-androst-1-en-3β,17β-diol); 1-androstendion (5α-xxxxxxx-1-xx-3,17-xxxx); bolandiol (estr-4-en-3β,17β-diol); xxxxxxxxxx; boldenon; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazol); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); drostanolon; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); fluoxymesteron; formebolon; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); kalusteron; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); metenolon; xxxxxxxxxxx; metasteron (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; metribolon (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; norethandrolon; norklostebol; xxxxxxxx; oxandrolon; oxymesteron; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx exogenně:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA), xxxxxxxxxxx x xxxxxx xxxxxxxxxx x isomery, xxx xx x xxxxxxxx xxxxx na ně:
5α-xxxxxxxxx-3α,17α-xxxx | 5-androstendion (xxxxxxx-5-xx-3,17-xxxx) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-xxxxxxxxx-3β,17β-xxxx | xxxxxxxxxxxxxx |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-hydroxy-5αandrostan-17-on |
xxxxxxx-4-xx-3α,17β-xxxx | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-5-xx-3β,17α-xxxx | 7α-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17β-xxxX | 7-xxxx-XXXX |
androst-5-en-3β,17α-diol | 19-xxxxxxxxxxxxxx |
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) | 19-xxxxxxxxxxxxxxxxx |
2. Ostatní xxxxxxxxxx xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, zilpaterol, ale xx s xxxxxxxx xxxxx xx xx.
Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx x látce, xxxxxx xxxx xxxx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "endogenní " xx vztahuje k xxxxx, kterou může xxxx xxxxxxxxxx xxxxxxxxx. |
X2. PEPTIDOVÉ XXXXXXX, RŮSTOVÉ FAKTORY X XXXXXXXX XXXXX
Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx faktory xxxx zakázány:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (EPO), xxxxxxxxxxx (dEPO), stabilizátory xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), peginesatid /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (CG) x Xxxxxxxxxxxx hormon (XX) u mužů;
3. Xxxxxxxx;
4. Xxxxxxxxxxxxxx;
5. Růstový xxxxxx (GH), xxxxxxxxxxxxx xxxxxxx faktory (FGFs), xxxxxxxxxxxx xxxxxxx faktor (XXX), xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx faktor xxxxxxxx z krevních xxxxxxxx (PDGF) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX), xxxxxx xxxx xxxxxxxxx xxxx xxxxxxx xxxxxxx ovlivňující syntézu xxxx xxxxxxxxx xxxxxxxx xxxxx, šlach x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx xxxxxxxx xxxx ovlivňující xxxx xxxxxxxxx vláken;
x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.
X3. XXXX2- AGONISTÉ
Xxxxxxx xxxx-2 agonisté (xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx xxxxxxxx xxxxx salbutamolu (xxxxxxxxx 1600 xxxxxxxxxx xx 24 hodin), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) x salmeterolu pokud xxxx podány v xxxxxxxx x souladu x xxxxxxxxxxx léčebným xxxxxxx xxxxxxx.
Přítomnost xxxxxxxxxxx x moči x xxxxxxxxxxx xxxxx xxx 1000 ng/ml x xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 30 ng/ml xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, ale xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx nález, xxxxx sportovec xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx výsledek xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx inhalační xxxxx xxxxx než xxxx xxxxxxx xxxxxxx.
X4. XXXXXXXXX X METABOLICKÉ XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx s omezením xxxxx xx ně.
2. Xxxxxxxxxx modulátory xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxxxx:
Xxxxxxxxx, tamoxifen, xxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, ale xx x xxxxxxxx pouze xx ně.
4. Xxxxx modifikující funkce xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx: Receptor xxxxx aktivovaný xxxxxxxxxxxxxx xxxxxxxxxxxxx /Peroxisome Proliferator Xxxxxxxxx Xxxxxxxx δ (PPARδ) xxxxxxxx/ (xxxx. XX 1516) x Agonisté xxxxxxxxxxxxxxx xxx xxxxxxxxxx XXX x xxxxxxxxxxx s XXXX delta /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (xxxx. XXXXX)
S5. DIURETIKA X XXXXXXX XXXXXXXXX XXXXX
Xxxxxxxxx xxxxx xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, dextranu, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx a xxxxx xxxxx s podobnými xxxxxxxxxxxx účinky. Xxxxxxx xxxxxxxx felypressinu pro xxxxx xxxxxxxx xxxx xxxxxxxx.
Diuretika zahrnují:
Xxxxxxxxxxxx, amilorid, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, indapamid, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxxxx a xxxxxxxxxxxx, které nejsou xxxxxxxx).
Xxx xxxxxxx (Xxx Xxxxxxx, případně Xxxx Soutěž) xxxxxxxxxxx xxxxxxxx látky se xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx látkou xx xxxxxxxxxx udělení specifické Xxxxxxxxxxxx xxxxxxx xx xxxx xxxxx xxxxx x xx, která xxx byla xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.
XXXXXXXX METODY
M1. XXXXXXXXX PŘENOSU XXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Xxxxxx xxxxxx, xxxxxx použití xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx xxxx xxxx červených xxxxxxx a xxx xxxxxxxxx xxxxxxxx jakéhokoliv xxxxxx.
2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx dodávky xxxxxxx, xxxxxxxxxx modifikované xxxxxxxxxxxxx xxxxxxxx (např.krevní xxxxxxxx xxxxxxxx na xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx xx x xxxxxxxx xxxxx na xx. Xxxxxxxx xxxxxxx xxxxxxxx xxxx.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, za xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx kontrole xx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. proteázami) xxxx, xxx xx x xxxxxxxx xxxxx xx ně.
2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx než 50 xx xx 6 xxxxx xxxx xxxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx vyšetřovacích xxxxx.
3. Xxxxxxxx xxxxx, manipulace a xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxx krve xx xxxxxxxxx xxxxxxx xx xxxxxxxx.
M3. GENOVÝ XXXXXX
X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxxxx kyselin xxxx jejich sekvencí;
2. Použití normálních xxxx xxxxxxxxx modifikovaných xxxxx;
XXXXX X METODY XXXXXXXX XXX XXXXXXX |
Xxxxx kategorií SO xx X5 x X1 xx M3 xxxxxxxxx xxxx xxxx Xxx Soutěži xxxxxxxx x následující skupiny:
XXXXXXXX LÁTKY
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx (xxxxxx xxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx xxxxxxxx, x xxxxxxxx derivátů xxxxxxxxx x případě xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2012*.
Xxxxxxxxxxx xxxxxxxx:
(x) Nespecifická xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, amifenazol, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, fenetylin, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, kropropamid, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, modafinil, norfenfluramin, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx v xxxxx xxxxxxxx, je Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx stimulancia (příklady):
Xxxxxxxxx**, xxxxx***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, fenbutrazát, xxxxxxxxxxx, xxxxxxxxxxxxx, heptaminol, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, meklofenoxát, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), niketamid, norfenefrin, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, propylhexedrin, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, strychnin, xxxxxxxxxxxxx a xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.
* Xxxxxxxxxxx xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2012 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
** Xxxxxxx xxxxxx adrenalinu (xxxx. xxxxx, xxxx xxxxxxxx) xxxx jeho xxxxxx xxxxxxxx x xxxxxxxxx anestetiky není xxxxxxxx.
*** Xxxxx xx xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 mikrogramů x 1 xx xxxx.
**** Efedrin x xxxxxxxxxxxxx xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx moči.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx jeho xxxxxxxxxxx x xxxx xx xxxxx než 150 xxxxxxxxxx na xxxxxxxx
X7. NARKOTIKA
Xxxxxxxx xx xxxxxxxxxxx:
Buprenorfin, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), fentanyl x xxxx xxxxxxxx, xxxxxxxxxxx, metadon, morfin, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.
X8. XXXXXXXXXXX
Xxxxxxxx (xxxx. hašiš, xxxxxx x marihuana) xxxx syntetický delta9tetrahydrokanabinol (XXX) a xxxxxxxxxxxxxx (xxxx. "Xxxxx" /obsahující XXX018, JWH073/ x XX-210) xxxx zakázané.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.
XXXXX XXXXXXXX V XXXXXXXX XXXXXXXX |
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Detekce xx bude xxxxxxxx xxxxxxxx zkouškou a/nebo xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 x/x.
∙ Automobilový xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx motorismus (XXX)
X2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx Při Soutěži x následujících sportech.
∙ Automobilový xxxxx (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (WCBS)
∙ Xxxxx (XXX)
∙ Golf (XXX)
∙ Xxxxxxx x xxxxxxx (FIQ)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx (FAI)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx také Mimo xxxxxx)
∙ Xxxxxxxx (XXX) - skoky xx lyžích a xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx,x xxxxxxxxx X-xxxxx x "big xxx"
∙ Xxxxxxxx x xxxxxxx xxxxxx (XXXX)
∙ Xxxxxxx (ISSF, XXX) (zakázané také Xxxx soutěž)
∙ Xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XxX)
Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, alprenolol, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, oxprenolol, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, timolol, xxx xx x xxxxxxxx pouze na xx.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 97/2012 Sb. x. x. nabyl xxxxxxxxx xxxx 25.12.2012.
Xxxxxx xxxxxxx č. 97/2012 Xx. x. x. xxx zrušen xxxxxxx předpisem č. 98/2013 Sb. m. s. x účinností xx 20.12.2013.
Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx xxxxxxxx xxxxxxxx x odkazech xxxx xxxxxxxxxxxxx, xxxxx se xxxx netýká xxxxxxxxx xxxxx shora uvedeného xxxxxxxx xxxxxxxx.